All manuscripts
Publications CAR T Cells

Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective

Published Journal Frontiers in Oncology

Share
6 pages Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective

Overview

This perspective argues that a decentralized, hospital-based model of autologous CAR T manufacturing suits low- and middle-income countries better than the centralized one. Its CliniMACS Prodigy validation runs were costed at 35,100 USD per patient, against about 475,000 USD for Kymriah in the U.S.

What this paper found

A decentralized, hospital-based model of autologous CAR-T manufacturing on automated closed platforms is argued to suit low- and middle-income countries such as India better than the centralized pharmaceutical model. The perspective contrasts the two models across apheresis, manufacturing and administration. Point-of-care production avoids cold-chain transport and cryopreservation, needs less cleanroom infrastructure and labour, and shortens arm-to-arm time. An Indian hospital facility estimated 35,100 USD per patient for preclinical validation runs on CliniMACS Prodigy, against about 475,000 USD for Kymriah in the United States. Barriers include absent national guidelines, scarce GMP-grade lentivirus, unclear cleanroom grading and limited funding.

Note: This is a perspective article without original experimental data; cost figures come from an external estimate for preclinical validation runs and exclude vector acquisition.

Unlike majority of cancer therapies, CAR-T (autologous) requires to be manufactured de novo for each patient by genetic modification of their own T-cells. — Sharanya Ramakrishnan, Jeevan Kumar, Suvro Sankha Datta, Vivek Radhakrishnan, Reena Nair, Mammen Chandy, Frontiers in Oncology

Study details

Authors
Sharanya Ramakrishnan, Jeevan Kumar, Suvro Sankha Datta, Vivek Radhakrishnan, Reena Nair, Mammen Chandy
Institution
Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India · Department of Transfusion Medicine, Tata Medical Center, Kolkata, India
Journal
Frontiers in Oncology
Year
2022
PMID / PMC
PMID: 36531042 · PMC
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy

Explore related

Full citation

Ramakrishnan S, Kumar J, Datta SS, Radhakrishnan V, Nair R, Chandy M. Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective. Front Oncol. 2022;12:1062296.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →